FluMist can't compete in flu vax study

FluMist just got a big thumb's down in a study reviewing vaccine response in more than a million U.S. soldiers.

Looking over a period of three years, researchers found that the traditional intramuscular flu jab led to a 54 percent reduction in visits to a doctor's office compared with only a 21 percent reduction for the intranasal vaccine FluMist.

FluMist was approved to help guard children from the flu but the New York Times notes that the intranasal vaccine is increasingly popular among adults. But in the 2004-05 flu season adults taking FluMist were even more likely to end up in the hospital than patients who had received no treatment.

Dr. Chris Ambrose, the director of medical affairs for MedImmune, counters that their data indicates a much better response to FluMist among children.  

- read the article in the New York Times

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.